NASDAQ:GMAB Genmab A/S (GMAB) Stock Price, News & Analysis $27.52 -0.17 (-0.61%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$27.46▼$27.9150-Day Range$24.85▼$28.4852-Week Range$24.53▼$38.80Volume370,163 shsAverage Volume577,660 shsMarket Capitalization$18.20 billionP/E Ratio22.93Dividend YieldN/APrice Target$45.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Genmab A/S alerts: Email Address Genmab A/S MarketRank™ Stock AnalysisAnalyst RatingHold2.46 Rating ScoreUpside/Downside66.4% Upside$45.80 Price TargetShort InterestHealthy0.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.70Based on 7 Articles This WeekInsider TradingN/AProj. Earnings Growth23.14%From $1.21 to $1.49 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.71 out of 5 starsMedical Sector47th out of 910 stocksPharmaceutical Preparations Industry17th out of 426 stocks 4.2 Analyst's Opinion Consensus RatingGenmab A/S has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 8 buy ratings, 3 hold ratings, and 2 sell ratings.Amount of Analyst CoverageGenmab A/S has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Genmab A/S's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.34% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genmab A/S has recently decreased by 26.69%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GMAB. Previous Next 3.2 News and Social Media Coverage News SentimentGenmab A/S has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Genmab A/S this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for GMAB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows3 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by InstitutionsOnly 7.07% of the stock of Genmab A/S is held by institutions.Read more about Genmab A/S's insider trading history. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Genmab A/S are expected to grow by 23.14% in the coming year, from $1.21 to $1.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 22.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 22.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.06.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 0.88. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genmab A/S's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Gold RepublicChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. About Genmab A/S Stock (NASDAQ:GMAB)Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Read More GMAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMAB Stock News HeadlinesSeptember 6 at 4:15 AM | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Stock Rating Reaffirmed by Morgan StanleySeptember 5 at 6:45 AM | markets.businessinsider.comGenmab’s Hold Rating: Balancing Stability and UncertaintySeptember 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.September 1, 2024 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Short Interest Down 26.7% in AugustAugust 30, 2024 | americanbankingnews.comQ3 2024 EPS Estimates for Genmab A/S (NASDAQ:GMAB) Raised by HC WainwrightAugust 28, 2024 | ca.finance.yahoo.comGMAB Sep 2024 35.000 callAugust 28, 2024 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Receives "Buy" Rating from HC WainwrightAugust 26, 2024 | globenewswire.comGenmab to Present at Morgan Stanley 22nd Annual Global Healthcare ConferenceSeptember 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.August 23, 2024 | seekingalpha.comGenmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On AcasunlimabAugust 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Genmab Following Epcoritamab’s European Approval and Strong Pipeline PotentialAugust 19, 2024 | globenewswire.comTEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular LymphomaAugust 16, 2024 | globenewswire.comGenmab Announces Changes to its Executive CommitteeAugust 13, 2024 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsAugust 13, 2024 | globenewswire.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseAugust 12, 2024 | seekingalpha.comGenmab A/S 2024 Q2 - Results - Earnings Call PresentationAugust 12, 2024 | marketwatch.comGenmab A/SAugust 9, 2024 | finanznachrichten.deGenmab A/S: Genmab Updates 2024 Financial GuidanceSee More Headlines Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Confirmed)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GMAB CUSIPN/A CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees2,204Year Founded1999Price Target and Rating Average Stock Price Target$45.80 High Stock Price Target$53.00 Low Stock Price Target$31.00 Potential Upside/Downside+66.4%Consensus RatingHold Rating Score (0-4)2.46 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$1.20 Trailing P/E Ratio22.93 Forward P/E Ratio22.74 P/E Growth0.88Net Income$631.91 million Net Margins29.06% Pretax Margin39.35% Return on Equity17.48% Return on Assets15.13% Debt Debt-to-Equity RatioN/A Current Ratio5.03 Quick Ratio5.02 Sales & Book Value Annual Sales$19.02 billion Price / Sales0.96 Cash Flow$1.23 per share Price / Cash Flow22.42 Book Value$6.76 per share Price / Book4.07Miscellaneous Outstanding Shares661,299,000Free Float651,115,000Market Cap$18.20 billion OptionableOptionable Beta0.99 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Jan G.J. van de Winkel Ph.D. (Age 63)Co-Founder, President & CEO Comp: $2.9MMr. Anthony Pagano (Age 46)Executive VP & CFO Comp: $1.03MMr. Anthony Mancini (Age 53)Executive VP & COO Comp: $1.14MMs. Birgitte Stephensen M.Sc. (Age 63)Executive VP & Chief Legal Officer Comp: $637.57kMr. Christopher Cozic (Age 45)Executive VP & Chief People Officer Comp: $782.47kDr. Martine J. van Vugt Ph.D. (Age 53)Executive VP & Chief Strategy Officer Comp: $695.53kMr. Martin Schultz (Age 48)Senior Director of Clinical Operations & Non-Independent Director Comp: $115.92kDr. Judith V. Klimovsky M.D. (Age 66)Executive VP & Chief Development Officer Comp: $1.17MDr. Tahamtan Ahmadi (Age 51)Executive VP, Chief Medical Officer & Head of Experimental Medicines Comp: $1.12MDr. Mijke Zachariasse Ph.D. (Age 50)Senior Director, Head of Antibody Research Materials & Non-Independent Director Comp: $159.39kMore ExecutivesKey CompetitorsTakeda PharmaceuticalNYSE:TAKModernaNASDAQ:MRNABioNTechNASDAQ:BNTXTeva Pharmaceutical IndustriesNYSE:TEVABeiGeneNASDAQ:BGNEView All CompetitorsInstitutional OwnershipSanctuary Advisors LLCBought 53,893 shares on 9/5/2024Ownership: 0.008%Point72 Asset Management L.P.Bought 18,184 shares on 8/19/2024Ownership: 0.003%Creative PlanningSold 16,761 shares on 8/16/2024Ownership: 0.003%Millennium Management LLCSold 92,934 shares on 8/15/2024Ownership: 0.058%Bank of Montreal CanSold 1,803 shares on 8/14/2024Ownership: 0.012%View All Institutional Transactions Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Genmab A/S: Genmab A/S has a strong average rating of "Hold" from analysts, indicating stability in the company's performance. Recent price target updates from analysts suggest a potential upside of 76.37% from the current stock price, providing a growth opportunity for investors. Institutional investors have been increasing their stakes in Genmab A/S, indicating confidence in the company's future prospects. Genmab A/S has a market capitalization of $18.75 billion, reflecting the company's significant size and presence in the market. The company's 12-month low of $24.53 provides a potential entry point for investors looking to buy at a lower price. Cons Investors should be bearish about investing in Genmab A/S for these reasons: Despite some positive analyst ratings, there are still sell recommendations on the stock, indicating potential risks associated with investing in Genmab A/S. The stock has been trading down recently, showing a 1.0% decrease, which may raise concerns about short-term performance. Genmab A/S has a beta of 0.97, suggesting that the stock's price is closely correlated with market movements, potentially leading to higher volatility. The company's P/E ratio of 23.58 may indicate that the stock is currently overvalued compared to its earnings, posing a risk for investors. Genmab A/S has a 1-year high of $39.81, which could signal resistance at higher price levels and limit potential short-term gains for investors. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 19, 2024. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com. GMAB Stock Analysis - Frequently Asked Questions How have GMAB shares performed this year? Genmab A/S's stock was trading at $31.84 on January 1st, 2024. Since then, GMAB shares have decreased by 13.6% and is now trading at $27.52. View the best growth stocks for 2024 here. How were Genmab A/S's earnings last quarter? Genmab A/S (NASDAQ:GMAB) issued its earnings results on Thursday, August, 8th. The company reported $0.22 EPS for the quarter, missing analysts' consensus estimates of $0.29 by $0.07. The company earned $779.50 million during the quarter, compared to analysts' expectations of $734.60 million. Genmab A/S had a trailing twelve-month return on equity of 17.48% and a net margin of 29.06%. When did Genmab A/S IPO? Genmab A/S (GMAB) raised $503 million in an initial public offering on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. Who are Genmab A/S's major shareholders? Genmab A/S's top institutional investors include Renaissance Technologies LLC (0.22%), Envestnet Asset Management Inc. (0.15%), Marshall Wace LLP (0.10%) and American Century Companies Inc. (0.07%). How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC) and Pfizer (PFE). This page (NASDAQ:GMAB) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
